Who makes VSL #3 112.5 Capsule?

VSL #3 112.5 Capsule is developed by University of California, Los Angeles.

What development phase is VSL #3 112.5 Capsule in?

VSL #3 112.5 Capsule is in Phase 1.

Last reviewed 2026-05-13 · How we verify

VSL #3 112.5 Capsule

University of California, Los Angeles · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	VSL #3 112.5 Capsule
Sponsor	University of California, Los Angeles
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Alcoholic Liver Disease and the Gut Microbiome (NA)
Effect of Probiotic Administration on Gut Flora Composition (NA)
Study to Determine Efficacy of Probiotics in Irritable Bowel Syndrome (PHASE3)
Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life (PHASE2, PHASE3)
Changes in Gastrointestinal Microbiota Using VSL#3 in Patients With IBS-D (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VSL #3 112.5 Capsule CI brief — competitive landscape report
VSL #3 112.5 Capsule updates RSS · CI watch RSS
University of California, Los Angeles portfolio CI